Imunon, Inc. 8-K

What Happened
Imunon, Inc. announced in an 8-K that Executive Vice President and Chief Scientific Officer Khursheed Anwer informed the company he will retire effective February 20, 2026. The company and Dr. Anwer executed a Retirement and Consulting Agreement on February 4, 2026 under which he will provide consulting services through December 31, 2026. The filing states his departure is without any disagreements with management.

Key Details

• Retirement Date: February 20, 2026.
• Consulting Period: From Retirement Date through December 31, 2026.
• Consulting pay: $10,000 monthly retainer during the Consulting Period.
• Separation benefits: payment of any accrued unpaid salary and unreimbursed expenses within 30 days of retirement; continued payment of his base salary as severance for 12 months after the Retirement Date; company-paid COBRA coverage for 12 months.
• Agreement includes a customary release of claims in the company’s favor and is filed as Exhibit 10.1 to the 8-K.

Why It Matters
This is an executive leadership change (Item 5.02) that affects Imunon’s scientific leadership but includes transition measures to maintain continuity: a consulting arrangement and one-year severance/benefits. Investors should note the company’s disclosed near-term cash obligations (the $10,000/month retainer plus continuation of base salary and COBRA coverage), though the filing does not disclose Dr. Anwer’s base salary amount. The filing signals an orderly transition with no reported management dispute.